Triclosan is a broad-spectrum antibacterial agent that inhibits bacterial fatty acid synthesis at the enoyl-acyl carrier protein reductase (FabI) step. Resistance to triclosan in Escherichia coli is acquired through a missense mutation in the fabI gene that leads to the expression of FabI [ 
the introduction of a cis double bond into the growing acyl chain at the ␤-hydroxydecanoyl-ACP step and most efficiently catalyzes dehydration of short-chain ␤-hydroxyacyl-ACPs, whereas the FabZ dehydratase has a broader substrate specificity (5) . The last reaction in each elongation cycle is catalyzed by enoyl-ACP reductase (FabI). Contrary to the initial conclusion that there were two enoyl-ACP reductases, based on assays in crude extracts (6) , E. coli cells possess only a single NADH-dependent enoyl-ACP reductases encoded by the fabI gene that utilizes all chain lengths (7) .
The importance of fatty acid biosynthesis to cell growth and function makes this pathway an attractive target for the development of antibacterial agents. Two important control points in the cycle are the condensing enzymes and the enoyl-ACP reductase (8, 9) , and both reactions are targeted by compounds that effectively inhibit fatty acid synthesis. Two natural products, cerulenin and thiolactomycin, are potent antibiotics that function by specifically inhibiting the condensing enzyme reactions (for reviews, see Refs. 3, 10) . The diazaborines, a class of heterocyclic antibacterials, inhibit fatty acid biosynthesis by blocking the FabI step (11) . Resistance to the diazaborines arises from a missense mutation in the fabI gene that leads to the expression of a FabI[G93S] mutant protein (12, 13) . Similarly, the fabI analog in Mycobacterium tuberculosis, the inhA gene, encodes a cellular target for isoniazid and ethionamide. A point mutation in the inhA gene confers resistance to the drugs (14) . Both isoniazid and diazaborine bind at the substrate site of the respective enoyl-ACP reductases and covalently react with NAD ϩ to form tight binding bi-substrate complexes (15, 16) . Triclosan is a broad-spectrum antibacterial agent that enjoys widespread applications in a multitude of contemporary consumer products including, soaps, detergents, toothpastes, skin care products, cutting boards, and mattress pads (17) . Triclosan is widely thought to be a nonspecific biocide that attacks bacterial membranes (18 -20) , and if triclosan does not have a discrete mechanism of action, the acquisition of cellular resistance is unlikely. However, recent work reveals that resistant E. coli strains arise from missense mutations in the fabI gene (21, 22) and that triclosan and other 2-hydroxydiphenyl ethers directly inhibit fatty acid biosynthesis in vivo and FabI catalysis in vitro (22) . The goal of this study was to investigate the mechanism by which triclosan inhibits FabI. Purification of FabI and FabI[G93V]-The expression and purifica-tion of His-tag FabI was described previously (7) . The fabI G93V allele was amplified from the chromosome of the triclosan-resistant strain RJH108 (22) and ligated into the pET15b expression vector. DNA sequencing of the expression construct confirmed the presence of the single point mutation. The His-tagged FabI[G93V] was then expressed and purified to homogeneity by Ni 2ϩ affinity chromatography using the same methods as described for the wild-type FabI (7). Protein was determined by the method of Bradford (23) .
EXPERIMENTAL PROCEDURES

Materials-Sources
Spectrophotometric Assay of FabI-FabI activity was assayed spectrophotometrically by monitoring the decrease in absorption at 340 nm using an adaptation of the spectrophotometric assay used by Bergler et al. (24) . Standard reactions contained 100 M 8:1-NAC, 12 g of homogeneous FabI (7, 8) , 200 M NADH, 0.1 M sodium phosphate, pH 7.5, in a final volume of 300 l. The reactions were performed at 24°C in semimicro quartz cuvettes. The change in optical density was continuously monitored for 1 min, and the reaction rate was calculated from the slope of the trace. Triclosan was added to the final concentrations indicated in the figure legend from serially diluted stock solutions in Me 2 SO. The Me 2 SO concentration in all assays was maintained at 1.66%, which did not significantly affect FabI activity. The FabI specific activity in the absence of drugs under these experimental conditions was 0.36 mol/min/mg. Data points were the mean of duplicate assays, and the individual values were within Ϯ 5% of the average. in a final volume of 50 l. Samples were incubated at 24°C for 15 min and then separated using one of the two methods outlined above.
Structural Biology-Crystals of FabI were grown from hanging drops (6 l) containing 5 mg/ml FabI, 25 mM Tris, 150 mM NaCl, 0.5 mM dithiothreitol, 5 mg/ml NADH, 50 mM sodium acetate, 4% polyethylene glycol 4000 (w/v), pH 4.6. The drops were equilibrated against a reservoir (600 l) containing 100 mM sodium acetate, pH 4.6, and 8% polyethylene glycol 4000 (w/v). Large hexagonal bipyrimidal crystals appeared after equilibration for 1 day at 26°C and reached dimensions of 1.0 ϫ 0.5 ϫ 0.5 mm.
Crystals of the FabI-NAD ϩ -triclosan ternary complex were prepared by soaking pregrown crystals of FabI in solutions containing 10 mg/ml NAD ϩ , 10 mg/ml triclosan, 100 mM sodium acetate, pH 4.6, and 10% polyethylene glycol 4000 (w/v) for 7 days. X-ray diffraction data were collected on the IMCA beamline (17-ID) at the Advanced Photon Source at the Argonne National Laboratory. The crystals used for data collection were first transferred to a cryoprotectant buffer containing 100 mM sodium acetate, pH 4.6, 10% polyethylene glycol 4000 (w/v), 25% glycerol (v/v) for 1 h and then flash-frozen in a stream of liquid nitrogen. X-ray data to 1.8-Å resolution were collected at 100 K using synchrotron X-radiation at a 1.0-Å wavelength and a Bruker 2 ϫ 2 mosaic CCD x-ray detector. The x-ray data were then processed using the SAINT (Bruker x-ray, Madison, WI) program package.
Crystals of the FabI-NAD ϩ -triclosan complex were hexagonal, space group P6 1 22 (number 178) with unit cell dimensions a ϭ b ϭ 79.70 and c ϭ 327.7 Å and two molecules of the ternary complex in the asymmetric unit. These crystals were isomorphous to those of the FabI-NAD ϩ -diazaborine complex reported by Baldock et al. (15) . The FabI structure was initially refined as a rigid body using XPLOR, and the positions and conformation of the bound NAD ϩ and triclosan molecules were determined from Fo-Fc difference electron density maps. In addition, the positions of the 185 tightly bound water molecules were determined from subsequent residual electron density maps. The entire structure containing 2 molecules of the FabI-NAD ϩ -triclosan complex and 185 water molecules was refined to a crystallographic R-factor of 0.232 using data from 8.0 to 1.8 Å resolution. Residues 194 -210 were disordered in the structure. Solvent-accessible surface areas were calculated using a 1.4-Å probe with the SOLVATION module of the InsightII software (version 97.1, Molecular Simulations, Inc.). (22) and that a mutation in the fabI gene that results in the expression of a FabI[G93V] protein exhibited high level triclosan resistance (21, 22) . FabI[G93V] was cloned into the pET15b expression vector and expressed and purified as described under "Experimental Procedures." The apparent K m values for the two substrates were determined for both the wild-type and mutant protein. The wild-type protein had an apparent K m for NADH of 15 Ϯ 1 M, whereas the FabI[G93V] exhibited an apparent K m for NADH of 8 Ϯ 2 M. Thus, there were not major differences between the kinetic constants for NADH in the wild-type and mutant protein. We also measured the apparent K m for the enoyl substrate using 4:1-NAC. This substrate analog was selected for these experiments because it had the higher solubility in the assay buffer than 8:1-NAC. The apparent K m for 4:1-NAC was 25 Ϯ 5 mM for FabI compared with 15 Ϯ 2.2 mM for FabI[G93V]. The V max for FabI was 4.4 mol/min/mg, and for FabI[G93V], the V max was 3.6 mol/min/ mg. These data illustrated that FabI and FabI[G93V] had similar specific activities and substrate and cofactor binding characteristics.
RESULTS
Biochemical Characterization of the Triclosan-resistant Mutant, FabI[G93V]-Previous work showed that FabI was inhibited by triclosan
Triclosan Inhibition of FabI and FabI[G93V]-The observation that cells expressing the FabI[G93V]
protein have a minimum inhibitory concentration for triclosan that was 64-fold higher than the wild-type strain (0.5 compared with 32 g/ml) (22) suggested that the FabI[G93V] protein would be refractory to triclosan inhibition in vitro. We directly tested this assumption using the spectrophotometric FabI assay and found that both FabI and FabI[G93V] were inhibited by triclosan (Fig. 1) . The IC 50 for FabI (2 M) was lower than the IC 50 for FabI[G93V] (10 M). This Ϸ5-fold increase in the IC 50 for FabI[G93V] was consistent with increased resistance of the enzyme to triclosan inhibition; however, the magnitude of this difference was significantly less than was predicted from the 64-fold difference in the effectiveness of triclosan against the mutant strain.
This unexpected discrepancy between the minimum inhibitory concentration and IC 50 data led us to examine the mechanism of FabI inhibition by triclosan in more detail. The data in Fig. 1 was obtained by starting the assay with the addition of FabI and measuring the initial rate of NADH oxidation from (Fig.  2) . Although there was an initial burst of activity in the presence of triclosan, within 3 min of the start of the experiment, FabI catalysis essentially ceased ( Fig. 2A) 4A ). An apparent association constant (K) of 2.5 M -1 for NAD ϩ in the presence of triclosan was calculated by analysis of the data using a double-reciprocal plot (Fig. 4B ). There was no indication of cooperative binding or the existence of more than a single class of sites by analysis of the data using a Scatchard plot (not shown). In contrast, we detected virtually no binding of [ 3 H]NAD ϩ to FabI in the absence of triclosan (Fig. 4A) . The affinity of FabI for NAD ϩ was so low that we measured only trace levels of [ 3 H]NAD ϩ binding to the free enzyme by this technique. Therefore, we examined the effectiveness of NAD ϩ as a product inhibitor of FabI using the spectrophototmetric assay. NAD ϩ was a poor inhibitor of the FabI reaction, with 50% inhibition occurring between 10 and 20 mM NAD ϩ . These data indicated a very low apparent affinity of FabI for NAD ϩ in the 10 -50 mM range (not shown). The filter binding assay was next used to examine the effect of triclosan concentration on NAD ϩ binding to FabI (Fig. 5) . The association of [ 3 H]NAD ϩ with FabI was dependent on the concentration of triclosan and saturable (Fig. 5A) . The apparent K for triclosan binding was calculated as 4.2 M -1 (Fig. 5B) . Thus, in the presence of triclosan, the affinity of FabI for NAD ϩ increased by approximately 4 orders of magnitude (Ͼ10 mM to 2.5 M -1 ).
Structure of the FabI-NAD ϩ -triclosan Ternary Complex-
The binding studies suggested that the basis for the potency of triclosan as a FabI inhibitor was because of the formation of a high affinity FabI-NAD ϩ -triclosan ternary complex. Determining the structure of the FabI-NAD ϩ -triclosan ternary complex by x-ray crystallography directly tested this idea (see "Experimental Procedures"). Triclosan bound noncovalently in a location adjacent to the nicotinamide portion of NAD ϩ (Fig. 6A ). There was 494.7 Å 2 of surface area buried between triclosan and the protein and 238.5 Å 2 of surface area buried at the interface with NAD ϩ . The diphenyl ether of triclosan adopted a conformation with a dihedral angle of about 90°between the two phenyl rings of the inhibitor. The 2-hydoxy-3-chlorophenyl ring formed a parallel stack with the nicotinamide ring of the 
FabI-NAD
ϩ Triclosan Ternary Complexco-factor with an interplanar stacking distance of 3.4 Å. In addition to the nicotinamide ring, the hydroxychlorophenyl ring was surrounded by hydrophobic side chains on the protein including Tyr-146 and Tyr-156. The 2Ј-hydroxyl group of triclosan was involved in two strong hydrogen bonds. One bond was with the 2Ј-hydroxyl group of the nicotinamide ribose, and the second was to the phenolic hydroxyl group of Tyr-156. The 2,4-dichlorophenyl ring of triclosan was rotated 90°of the plane of the hydroxychlorophenyl group. The chlorine substituent in the 4-position of the phenyl ring accepted a hydrogen bond from the backbone amide of Ala-95 and formed hydrophobic contacts with the side chain of Met-159. These data supported the concept that the formation of a stable, ternary FabI-NAD ϩ -triclosan complex accounted for the effective inhibition of the FabI reaction by this drug.
DISCUSSION
The formation of a ternary FabI-NAD ϩ -triclosan complex accounts for the effectiveness of triclosan as an antibacterial agent. Triclosan binds to the enoyl substrate site on FabI, and tight binding of the drug requires interactions between both the protein and the NAD ϩ cofactor (Fig. 6A ). There is a strong similarity between the mode of triclosan NAD ϩ binding to FabI (Fig. 6A ) and the structure of the FabI-NAD ϩ -diazaborine complex described by Baldock et al. (15) (Fig. 6B) . The diazaborine compounds form covalent adducts with NAD ϩ at the FabI active site. The boron atom of the diazaborine is attached to the 2Ј-hydroxyl of the NAD ϩ ribose, and this is the same 2Ј-hydroxyl group that forms a hydrogen bond with the hydroxychlorophenyl hydroxyl of triclosan. The FabI-NAD These residues are also not observed in the native structure of FabI, but the positions of these residues are evident in the FabI-NAD ϩ -diazaborine structure (15) . If the loop seen in the FabI-NAD ϩ -diazaborine complex is modeled onto the triclosan complex structure, there are no conflicting contacts between triclosan and the protein. In this model Ile-200 is in van der Waals contact with the 2,4-dichlorophenyl ring of triclosan, and Phe-203 is in contact with the hydroxychlorophenyl group. These data support the conclusion that triclosan forms a ternary complex that acts as a dead-end inhibitor that effectively removes protein from the catalytic cycle. These results lead to the general conclusion that all 2-hydroxydiphenyl ether FabI inhibitors (22) (21, 22) . Although FabI[G93V] activity is still inhibited at high triclosan concentrations (Fig.  2B) , the drug is not capable of forming a stable complex with the reductase. Triclosan is neither a dead-end inhibitor of FabI[G93V] (Fig. 2) (Fig. 3) . These biochemical results are interpreted by modeling the Val-93 into the Gly-93 position in the structure of the triclosan complex. Gly-93 lies on one side of the substrate binding pocket, and the branched hydrophobic side chain of Val protrudes into the pocket and occupies the same space as the dichlorophenyl ring of triclosan (see Fig. 6 ). Therefore, we conclude that the substitution of Gly-93 with bulkier amino acid residues imparts resistance to 2-hydroxydiphenyl ethers because of steric interference.
Our identification of a ternary FabI-NAD ϩ -triclosan complex 
FabI-NAD
ϩ Triclosan Ternary Complexreinforces the conclusion that FabI is a specific intracellular target for triclosan. Triclosan permeabilizes the bacterial envelope (18 -20) , and these findings have justified the widespread and increasing use of triclosan in consumer personal care products based on the reasoning that bacteria would not acquire resistance to a nonspecific membrane disrupter. However, this type of evidence is not sufficient to conclude that a compound has nonspecific membrane effects, because agents that block fatty acid biosynthesis perturb membrane assembly by stopping phospholipid production. For example, the temperature-sensitive fabI mutant was initially designated envM because it was isolated through a genetic selection for strains with envelope-permeability defects (25) . Also, the diazaborine class of FabI inhibitors are known to perturb membrane function as well (12) . The first evidence that triclosan has a specific cellular target was provided by McMurray et al. (21) who found that triclosan-resistant strains have missense mutations in the fabI gene. The biochemical analysis of FabI inhibition by triclosan (22) and the delineation of its mechanism of binding (this study) provide definitive evidence that enoyl-ACP reductase is the primary site for triclosan action. Thus, the reported effects of triclosan on membrane structure and function are a consequence of its specific inhibition of fatty acid biosynthesis at the FabI step. The ability of E. coli to acquire genetic resistance to triclosan and related compounds through missense mutations in the fabI gene suggests that the widespread use of this drug will lead to the appearance of resistant organisms that will compromise the usefulness of triclosan. The ubiquitous occurrence of type II fatty acid synthase systems in bacteria and the essential nature of the FabI reaction make this enzyme an attractive target for antibacterial drugs. Accordingly, triclosan is effective against a broad spectrum of bacteria (17) , including multidrug-resistant Staphylococcus aureus (26, 27) . The design and development of second generation FabI inhibitors based on their ability to form ternary FabI-NAD ϩ -drug complexes will supplement the arsenal against a broad spectrum of bacteria. 
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